Zobrazeno 1 - 4
of 4
pro vyhledávání: '"John l. Slunecka"'
Autor:
John L. Slunecka, Matthijs D. van der Zee, Jeffrey J. Beck, Brandon N. Johnson, Casey T. Finnicum, René Pool, Jouke-Jan Hottenga, Eco J. C. de Geus, Erik A. Ehli
Publikováno v:
Human Genomics, Vol 15, Iss 1, Pp 1-18 (2021)
Abstract Increasing amounts of genetic data have led to the development of polygenic risk scores (PRSs) for a variety of diseases. These scores, built from the summary statistics of genome-wide association studies (GWASs), are able to stratify indivi
Externí odkaz:
https://doaj.org/article/44aab4150f6242ffbb1be42366bf54da
Autor:
Sanam Sane, Andre Hafner, Rekha Srinivasan, Daniall Masood, John l. Slunecka, Collin J. Noldner, Alex D. Hanson, Taylor Kruisselbrink, Xuejun Wang, Yiyang Wang, Jun Yin, Khosrow Rezvani
Publikováno v:
Molecular Oncology, Vol 12, Iss 10, Pp 1753-1777 (2018)
Overexpression of oncoproteins is a major cause of treatment failure using current chemotherapeutic drugs. Drug‐induced degradation of oncoproteins is feasible and can improve clinical outcomes in diverse types of cancers. Mortalin‐2 (mot‐2) is
Externí odkaz:
https://doaj.org/article/8142dff1e9974bd79806dd9c3d84c9be
Autor:
Erik A. Ehli, Jeffrey J. Beck, John L. Slunecka, René Pool, Jouke-Jan Hottenga, Matthijs D. van der Zee, Casey T. Finnicum, Brandon N. Johnson, Eco J. C. de Geus
Publikováno v:
Slunecka, J L, van der Zee, M D, Beck, J J, Johnson, B N, Finnicum, C T, Pool, R, Hottenga, J J, de Geus, E J C & Ehli, E A 2021, ' Implementation and implications for polygenic risk scores in healthcare ', Human Genomics, vol. 15, 46, pp. 1-18 . https://doi.org/10.1186/s40246-021-00339-y
Human Genomics, Vol 15, Iss 1, Pp 1-18 (2021)
Human Genomics
Human Genomics, Vol 15, Iss 1, Pp 1-18 (2021)
Human Genomics
Increasing amounts of genetic data have led to the development of polygenic risk scores (PRSs) for a variety of diseases. These scores, built from the summary statistics of genome-wide association studies (GWASs), are able to stratify individuals bas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::091abbc0e6fca5386b3d41f3b97fda3a
https://hdl.handle.net/1871.1/754cd848-fd37-40fe-a6df-b6ebaa05156c
https://hdl.handle.net/1871.1/754cd848-fd37-40fe-a6df-b6ebaa05156c
Autor:
Rekha Srinivasan, Jun Yin, Yiyang Wang, Daniall Masood, Alex D. Hanson, Collin J. Noldner, Xuejun Wang, Andre Hafner, Sanam Sane, Taylor Kruisselbrink, John l. Slunecka, Khosrow Rezvani
Publikováno v:
Molecular Oncology, Vol 12, Iss 10, Pp 1753-1777 (2018)
Molecular Oncology
Molecular Oncology
Overexpression of oncoproteins is a major cause of treatment failure using current chemotherapeutic drugs. Drug‐induced degradation of oncoproteins is feasible and can improve clinical outcomes in diverse types of cancers. Mortalin‐2 (mot‐2) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1af750bec9edf096aaddf7f1dc40959
https://doaj.org/article/8142dff1e9974bd79806dd9c3d84c9be
https://doaj.org/article/8142dff1e9974bd79806dd9c3d84c9be